Mitria Medical Partners With T45 Labs to Advance Its Mitral Valve Repair Therapy

October 1, 2026—Mitria Medical announced a partnership with T45 Labs, a Silicon Valley medtech incubator focused on minimally invasive cardiovascular technologies.

Inquis Launches Aventus Thrombectomy Catheter With 360° Directional Aspiration for PE

September 30, 2026—Inquis Medical, a developer of treatments for venous thromboembolic disease, announced the United States commercial launch of the latest Aventus catheter, which received FDA 510(k) clearance in July 2026.

ACASA-TAVI Study Compares Anticoagulant Versus Antiplatelet Therapy After TAVR to Reduce Clots

September 24, 2026—Findings from the ACASA-TAVI trial showed that anticoagulation after transcatheter aortic valve replacement (TAVR) reduced imaging signs of clot formation on a new valve compared with antiplatelet therapy, without compromising safety.

PRAGUE-26 Evaluates Interventional Strategy for PE in Intermediate-High–Risk Patients 

September 24, 2026—The PRAGUE-26 study, which is evaluating whether an interventional strategy can improve outcomes in patients with embolism, showed that catheter-directed thrombolysis (CDT) improved short-term clinical outcomes compared with standard anticoagulation therapy alone in patients with intermediate-high–risk pulmonary embolism (PE).

TAVR-First Versus PCI-First Strategies Studied in Patients with Severe AS and Concomitant CAD

September 24, 2026—A transcatheter aortic valve replacement (TAVR) first strategy was shown to be noninferior to a percutaneous coronary intervention- (PCI-) first strategy after 1-year follow-up, according to results from the TAVI PCI trial that were presented at the European Society of Cardiology’s ESC Congress 2026 and published simultaneously by Professor Barbara E. Stähli, MD, et al in The New England Journal of Medicine.

HighLife Raises Financing to Advance Its TMVR Program

September 24, 2026—HighLife SAS, which is headquartered in Paris, France, and focused on transcatheter solutions for structural heart disease, announced the completion of a €80 million financing round.

Mölnlycke Launches Biogel Radiation Protection Gloves

September 22, 2026—Mölnlycke Health Care US, LLC. announced the launch of the company’s range of Biogel radiation protection gloves, designed to reduce clinician hand exposure to scattered radiation during fluoroscopy-guided, interventional, and other image-dependent procedures.

Cordis Selution SLR Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis

September 21, 2026—Cordis announced that the FDA has approved the Selution SLR sirolimus drug-eluting balloon (DEB) for the treatment of coronary in-stent restenosis (ISR).